Roth Capital set a $6.00 target price on Acura Pharmaceuticals Inc. (NASDAQ:ACUR) in a report issued on Tuesday morning. The brokerage currently has a a buy rating on the specialty pharmaceutical company’s stock.
Separately, FBR & Co reiterated a buy rating and issued a $10.00 price target on shares of Acura Pharmaceuticals in a research note on Sunday, July 17th.
Shares of Acura Pharmaceuticals (NASDAQ:ACUR) traded down 4.7455% during trading on Tuesday, hitting $1.1301. 36,523 shares of the stock were exchanged. The stock’s market cap is $13.37 million. Acura Pharmaceuticals has a 52-week low of $1.04 and a 52-week high of $3.52. The firm has a 50 day moving average of $1.55 and a 200-day moving average of $2.11.
Acura Pharmaceuticals (NASDAQ:ACUR) last announced its quarterly earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, hitting analysts’ consensus estimates of ($0.28). Acura Pharmaceuticals had a negative net margin of 303.77% and a negative return on equity of 178.04%. Equities research analysts anticipate that Acura Pharmaceuticals will post ($1.05) earnings per share for the current fiscal year.
An institutional investor recently raised its position in Acura Pharmaceuticals stock. Renaissance Technologies LLC raised its position in Acura Pharmaceuticals Inc. (NASDAQ:ACUR) by 10.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 58,120 shares of the specialty pharmaceutical company’s stock after buying an additional 5,300 shares during the period. Renaissance Technologies LLC owned 0.49% of Acura Pharmaceuticals worth $164,000 as of its most recent SEC filing. Institutional investors and hedge funds own 32.63% of the company’s stock.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.